Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.
The present studies demonstrate that antisera directed against Streptococcus pneumoniae type 14 is opsonic for group B streptococci type III in a neutrophile-mediated bactericidal assay. Specificity was demonstrated by the observations that group B streptococci type III and S. pneumoniae type 14 adsorbed the opsonic activity of anti-S. pneumoniae type 14 antisera. Group B streptococci strain 090R (devoid of type antigens) and S. pneumoniae type 3, did not remove the opsonic activity of anti-S. pneumoniae type 14 serum. In vivo studies using a suckling rat model of neonatal group B streptococcal type III sepsis demonstrated that antisera directed against S. pneumoniae type 14 was highly protective.
D000818:Animals; D000907:Antibodies, Bacterial; D000918:Antibody Specificity; D001770:Blood Bactericidal Activity; D003429:Cross Reactions; D004195:Disease Models, Animal; D007167:Immunotherapy; D009504:Neutrophils / Q000276:immunology; D009895:Opsonin Proteins; D011135:Polysaccharides, Bacterial / Q000276:immunology; D051381:Rats; D013290:Streptococcal Infections / Q000628:therapy*; D013292:Streptococcus agalactiae / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*
D000907:Antibodies, Bacterial; D009895:Opsonin Proteins; D011135:Polysaccharides, Bacterial